SEC Form 10-K filed by Vivani Medical Inc.
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Get the next $VANI alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss data comparable to injections of semaglutide, active ingredient in Ozempic®/Wegovy®, with potential for once-yearly dosing Additional $8.25M equity financing which secures solid financial position into the second quarter of 2026, supporting further development of NPM-139 and NPM-115 programs in chronic weight management ALAMEDA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"),
Vivani Medical Announces $8.25M Private Placement Equity Financing
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of $1.12 per share, expected to result in gross proceeds of approximately $8.25 million in a p
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development for chronic weight management designed to guarantee medication adherence and potentially improve treatment tolerability by providing smooth and steady delivery of GLP-1 therapy ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company de
Director Williams Gregg bought $24,959 worth of shares (24,939 units at $1.00), increasing direct ownership by 0.53% to 4,720,800 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $4,100 worth of shares (4,000 units at $1.02), increasing direct ownership by 8% to 55,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $1,110 worth of shares (1,000 units at $1.11), increasing direct ownership by 2% to 51,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Director Williams Gregg bought $24,959 worth of shares (24,939 units at $1.00), increasing direct ownership by 0.53% to 4,720,800 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $4,100 worth of shares (4,000 units at $1.02), increasing direct ownership by 8% to 55,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $1,110 worth of shares (1,000 units at $1.11), increasing direct ownership by 2% to 51,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
SEC Form 10-K filed by Vivani Medical Inc.
10-K - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)
SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)
SEC Form SC 13D filed by Vivani Medical Inc.
SC 13D - Vivani Medical, Inc. (0001266806) (Subject)